VacZine Analytics  
MarketVIEW: RSV vaccines

Published: March 2016

Respiratory syncytial virus (RSV) is a leading cause of acute infant/childhood (< 5yrs) lower respiratory tract infections (ALRIs) and hospitalization. In particular, elderly adults and/or those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with malignancies are also at increased risk of RSV infection related complications. On a global basis, RSV is estimated to be responsible for 30 million episodes and 53,000 to 199,000 deaths per year, mostly children. 99% of deaths occur in developing countries.

An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in “at risk” groups. Currently a number of approaches are being pursued including live-attenuated viruses and/or recombinant proteins, the most advanced of which is from US biotech Novavax (RSV-F) who have recently entered Phase III trials with a VLP recombinant fusion protein. An adult filing is expected in 1H 2017.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new RSV vaccines across global markets1 to 2035. The model contains value ($ m) and volume (mio doses) predictions for infants (<1yrs) and various adult target groups (maternal, elderly and “at risk”). Differing RSV vaccine profiles (infant + maternal + elderly) and related issues such as differential pricing are also discussed along with an up-to-date review of epidemiology and the competitive environment, R&D pipeline.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV023 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2016 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains